Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement Dispute Between Novitas And iRhythm Hits An Impasse

Executive Summary

Local Medicare carrier Novitas raised its reimbursement rates for continuous cardiac monitoring, but iRhythm has concluded the rates are still too low and is preparing to discontinue serving this Medicare segment.

You may also be interested in...



iRhythm Is ‘Encouraged’ By Recent Reimbursement Discussions With Novitas

The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.

Updated: Reimbursement Questions Jeopardize Hillrom/Bardy Merger

Hillrom is reconsidering its planned $375m acquisition of Bardy Diagnostics because of Novitas' plan to cut Medicare reimbursement for extended cardiac monitoring. Bardy is suing to complete the deal.

Reimbursement For Long-Term Cardiac Monitoring Remains Uncertain, iRhythm Reports

Local Medicare carrier Novitas met with monitoring companies to discuss rates for long-term ECG monitoring, but no final decision on recently proposed rate cuts has been reached, iRhythm reported.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT143779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel